ea0081p91 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022
Leskovar Dunja
, Perica Drazen
, Sucur Nediljko
, Hauptman Ana Godan
, Pećin Ivan
Introduction: PCSK-9 (proprotein convertase subtilisin/kexin type 9) inhibitors are monoclonal antibodies that affect metabolism of low-density lipoprotein (LDL) by binding to the LDL receptor and promoting lysosomal degradation. There are two pcsk-9 inhibitors currently available: alirocumab (Praulent) and evolocumab (Repatha) which are administered subcutaneously every 14 days. Two large randomized studies (FOURIER, ODYSSEY) have shown that pcsk-9 inhibitors reduce LDL-chole...